Cytoreductive surgery

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, Research, Colon, Standard of care, GBM, Temozolomide, Peritoneum, Ovarian cancer, Therapy, RNA, IDMC, Cohort study, Head, Cholangiocarcinoma, National Health, Cytoreductive surgery, Pancreatic cancer, University, Safety, Cancer, PDAC, Patient, Gemcitabine, Glioblastoma, FOLFIRINOX, HIPEC, ASCEND, SOC, CRS, Chemistry, FDA, Glioma, Tumor microenvironment, Randomized controlled trial, Neck, Intramuscular injection, Pharmaceutical industry, Cryptocurrency

BASKING RIDGE, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Lisata and its development collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics.
  • The trial continues to make steady progress with enrollment completion expected by the fourth quarter of 2023 and data readouts expected in 2024.
  • We anticipate the first patient treated to be in the fourth quarter of 2023.
  • Lisata will hold a live conference call on Thursday, November 2, 2023, at 4:30 p.m. Eastern time to discuss financial results, provide a business update and answer questions.

Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)

Retrieved on: 
Thursday, September 28, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibroadenoma, European Society of Gynaecological Oncology, DLT, Congress Center, ESGO, University Clinical Centre in Gdańsk, Congress, Patient, Becquerel, Cytoreductive surgery, Istanbul Congress Center, Ovarian cancer, Safety, Pharmaceutical industry

"Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.

Key Points: 
  • "Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.
  • We believe this is an important first step as we advance the development of Radspherin® as a new treatment for patients with advanced ovarian cancer,” says CEO Anders Månsson.
  • The safety interim analysis after completion of the dose-limiting toxicity (DLT) period demonstrated that Radspherin® was well tolerated.
  • The highest dose of 7 MBq was recommended following the completion of dose escalation of 1-2-4-7 MBq, as no DLT was observed.

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Transfer, PDAC, Intramuscular injection, Neoplasm, Head, Colon, Chemistry, National Health, ASCEND, Patient, Randomized controlled trial, Cytoreductive surgery, HIPEC, Glioma, University, Therapy, GBM, Peritoneum, FDA, Technology transfer, Safety, Cholangiocarcinoma, Pancreatic cancer, Temozolomide, CRS, Cell, SOC, TPN, Running, Research, Ovarian cancer, CMC, Glioblastoma, FOLFIRINOX, RNA, Neck, Tumor microenvironment, Cryptocurrency, Pharmaceutical industry

BASKING RIDGE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “The second quarter generated strong momentum for Lisata.
  • We intend to use the results of ASCEND to explore possible conditional approvals globally and to design an optimized Phase 3 program.
  • The trial continues to make steady progress with enrollment completion expected by the fourth quarter of 2023 and data readouts in 2024.
  • Lisata will hold a live conference call on Tuesday, August 15, 2023, at 8:30 a.m. Eastern time to discuss financial results, provide a business update and answer questions.

On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery

Retrieved on: 
Monday, November 29, 2021
Patient, Ovarian cancer, Regulation of tobacco by the U.S. Food and Drug Administration, Folate, Cancer, Skin, Nausea, Indigestion, Technology, Lung cancer, Company, Perelman School of Medicine at the University of Pennsylvania, Surgeon, Palpation, Woman, Drug discovery, Priority review, NRG, Target, Doctor of Philosophy, Allergy, Obstetrics, University, Abdominal pain, Pregnancy, Cytoreductive surgery, Gynecologic Oncology (journal), Adult, Gynaecology, Lymph, Fast Track, Laboratory, Vomiting, Miscarriage, FDA, Purdue University College of Pharmacy, Nursing, and Health Sciences, Uncertainty, Associate, Multimedia, Flushing, Pain scale, Center, Itch, Birth, Food, Pharmaceutical industry, Birth control, Dairy product, Medical imaging

CYTALUX is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal.

Key Points: 
  • CYTALUX is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal.
  • CYTALUX serves as an adjunctive tool for surgeons to identify additional malignant ovarian cancer lesions that may have been missed by standard visual inspection and palpation, increasing the detection of more cancer during surgery.
  • "We are excited about the potential impact CYTALUX can have for patients in their fight against ovarian cancer.
  • CYTALUX, the Company's first product, received FDA approval for ovarian cancer in November 2021 and is being studied in the Phase 3 ELUCIDATE Trial for lung cancer in the US.

LI Cancer Patient First in NYS to Receive Aerosolized Chemotherapy Treatment

Retrieved on: 
Monday, March 8, 2021
Oncology, Health, Hospitals, Surgery, General Health, Radiology, Clinical trials, Cancer, Clinical medicine, Medicine, Oncology, Cancer treatments, Gastrointestinal cancer, Chemotherapy, Occupational safety and health, Ovarian cancer, Stomach cancer, Appendix cancer, Cytoreductive surgery

View the full release here: https://www.businesswire.com/news/home/20210308005852/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210308005852/en/
    Known as pressurized intraperitoneal aerosol chemotherapy, or PIPAC, the clinical trial offers a new treatment technique that administers chemotherapy laparoscopically in the form of a pressurized aerosol.
  • Importantly, PIPAC can be combined with IV chemotherapy in which case the tumor is being attacked from several directions.
  • It may be an option for patients with stomach, ovarian, colorectal, or appendix cancer if surgery to remove the cancer is not an option.
  • After that treatment Ms. Wolf underwent liver resection surgery in June followed by more chemotherapy.